Stewart Fisher - 12 Apr 2022 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Chief Scientific Officer
Signature
/s/ Jolie M. Siegel, Attorney-in-Fact
Issuer symbol
CCCC
Transactions as of
12 Apr 2022
Net transactions value
+$137,120
Form type
4
Filing time
12 Apr 2022, 20:41:18 UTC
Previous filing
16 Feb 2022
Next filing
27 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CCCC Common Stock Options Exercise $7,999 +2,156 +5% $3.71 45,462 12 Apr 2022 Direct
transaction CCCC Common Stock Options Exercise $129,121 +25,928 +57% $4.98 71,390 12 Apr 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CCCC Stock Option (Right to Buy) Options Exercise $0 -2,156 -5.7% $0.000000 35,572 12 Apr 2022 Common Stock 2,156 $3.71 Direct F1
transaction CCCC Stock Option (Right to Buy) Options Exercise $0 -25,928 -35% $0.000000 48,152 12 Apr 2022 Common Stock 25,928 $4.98 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 20% of this option vested and became exercisable on May 1, 2019, with the remainder vesting in 16 equal quarterly installments thereafter.
F2 This option vests and becomes exercisable in 20 equal quarterly installments, with the first installment vested on September 5, 2020.